相似文献
1
Antiarrhythmic drugs and polyneuropathy. The Collaborative Group for the Study of Polyneuropathy.
J Neurol Neurosurg Psychiatry. 1994 Mar;57(3):340-3. doi: 10.1136/jnnp.57.3.340.
2
Assessing the Risk for Peripheral Neuropathy in Patients Treated With Dronedarone Compared With That in Other Antiarrhythmics.
Clin Ther. 2018 Mar;40(3):450-455.e1. doi: 10.1016/j.clinthera.2018.01.015. Epub 2018 Feb 28.
3
Treatment of resistant atrial fibrillation. A meta-analysis comparing amiodarone and flecainide.
Arch Intern Med. 1995 Sep 25;155(17):1885-91.
4
Limitations to antiarrhythmic drug use in patients with atrial fibrillation.
CMAJ. 2004 Sep 28;171(7):741-5. doi: 10.1503/cmaj.1031277.
5
Management of patients with acute atrial fibrillation in the ED.
Am J Emerg Med. 2010 Oct;28(8):903-10. doi: 10.1016/j.ajem.2009.05.005. Epub 2010 Mar 25.
6
Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation.
Europace. 2011 Mar;13(3):329-45. doi: 10.1093/europace/euq450. Epub 2011 Jan 11.
7
Previous therapy with amiodarone increases the recurrence rate in successfully ablated patients with isthmus-dependent atrial flutter.
Rev Port Cardiol. 2004 Oct;23(10):1303-11.
8
[Combination anti-arrhythmic drug therapy].
Z Kardiol. 1992;81 Suppl 4:157-61.
9
Antiarrhythmic Drugs for Nonshockable-Turned-Shockable Out-of-Hospital Cardiac Arrest: The ALPS Study (Amiodarone, Lidocaine, or Placebo).
Circulation. 2017 Nov 28;136(22):2119-2131. doi: 10.1161/CIRCULATIONAHA.117.028624. Epub 2017 Sep 13.
10
Canadian Cardiovascular Society atrial fibrillation guidelines 2010: rate and rhythm management.
Can J Cardiol. 2011 Jan-Feb;27(1):47-59. doi: 10.1016/j.cjca.2010.11.001.
引用本文的文献
1
Flecainide-induced myalgias and weakness: a rare adverse reaction.
BMJ Case Rep. 2021 Apr 15;14(4):e238699. doi: 10.1136/bcr-2020-238699.
2
Treatment of Orthostatic Hypotension Due to Autonomic Dysfunction (Neurogenic Orthostatic Hypotension) in a Patient with Cardiovascular Disease and Parkinson's Disease.
Cardiol Ther. 2019 Jun;8(1):145-150. doi: 10.1007/s40119-018-0124-z. Epub 2019 Jan 9.
3
[Clinical aspects of treatment with amiodarone].
Herzschrittmacherther Elektrophysiol. 2017 Sep;28(3):307-316. doi: 10.1007/s00399-017-0516-0.
4
Amiodarone: the expanding antiarrhythmic role and how to follow a patient on chronic therapy.
Clin Cardiol. 1997 Jul;20(7):608-18. doi: 10.1002/clc.4960200706.
本文引用的文献
1
Amiodaron neuropathy: further arguments for human drug-induced neurolipidosis.
Eur Neurol. 1982 Jan-Feb;21(1):65-8. doi: 10.1159/000115456.
2
Adverse effects of antiarrhythmic drugs.
Drugs. 1981 Jan;21(1):23-45. doi: 10.2165/00003495-198121010-00002.
3
New antiarrhythmic drugs: their place in therapy.
Drugs. 1981 Nov;22(5):363-400. doi: 10.2165/00003495-198122050-00002.
4
Clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation.
N Engl J Med. 1981 Sep 3;305(10):539-45. doi: 10.1056/NEJM198109033051002.
5
Frequent neurologic toxicity associated with amiodarone therapy.
Neurology. 1984 May;34(5):669-71. doi: 10.1212/wnl.34.5.669.
6
Peripheral neuropathy induced by amiodarone chlorhydrate. A clinicopathological study.
J Neurol Sci. 1984 Feb;63(2):251-66. doi: 10.1016/0022-510x(84)90200-4.
7
Amiodarone neuropathy.
Neurology. 1983 May;33(5):643-5. doi: 10.1212/wnl.33.5.643.
8
Prediction of subclinical perhexiline neuropathy in a patient with inborn error of debrisoquine hydroxylation.
Am Heart J. 1983 Jan;105(1):159-61. doi: 10.1016/0002-8703(83)90297-1.
9
Perhexiline maleate induced lipidosis in human peripheral nerve and tissue culture: ultrastructural and biochemical changes.
Clin Toxicol. 1981 Dec;18(12):1405-9. doi: 10.3109/15563658108990349.
10
A classification of antiarrhythmic actions reassessed after a decade of new drugs.
J Clin Pharmacol. 1984 Apr;24(4):129-47. doi: 10.1002/j.1552-4604.1984.tb01822.x.
Zotero 插件